Lunit Inc.

Lunit Inc. is a South Korean medical artificial intelligence (AI) company dedicated to revolutionizing cancer diagnostics and therapeutics. Founded in 2013 and headquartered in Seoul, the company's core mission is to conquer cancer through the power of AI, aiming to make data-driven medicine a new standard of care. Lunit operates with a global presence, partnering with healthcare and biopharma leaders to deliver clinically proven solutions.

Lunit's product portfolio is primarily divided into two main suites: Lunit INSIGHT and Lunit SCOPE. Lunit INSIGHT offers AI solutions for cancer screening, including Lunit INSIGHT CXR for chest X-ray analysis, Lunit INSIGHT MMG for mammography, and Lunit INSIGHT DBT for 3D breast tomosynthesis. The Lunit SCOPE suite provides AI biomarker solutions for cancer treatment, encompassing products like Lunit SCOPE IO for immune phenotyping and Lunit SCOPE PD-L1 for PD-L1 scoring, alongside other tools for digital pathology and drug development. These solutions are utilized across medical imaging (radiology) and digital pathology market segments, supporting precision oncology and drug discovery.

Under the leadership of CEO Brandon Suh, Lunit has made significant strides in its market positioning and global expansion. A notable development in 2024 was the acquisition of Volpara Health Technologies, which has since been integrated and operates under the Lunit brand, significantly enhancing its breast health and screening capabilities, particularly in the U.S. market. The company has also secured FDA clearance for its next-generation 3D mammography AI and engages in strategic collaborations with major pharmaceutical companies like AstraZeneca and Daiichi Sankyo for AI-driven biomarker research. Lunit is publicly traded on the KOSDAQ exchange and is actively evolving into a comprehensive AI healthcare platform provider, integrating and managing medical big data across the entire cancer care continuum.